Seeking Alpha

Leerink Swann weighs in on Dendreon's (DNDN -21%) mixed Q1 results yesterday, downgrading the...

Leerink Swann weighs in on Dendreon's (DNDN -21%) mixed Q1 results yesterday, downgrading the shares to Market Perform on the back of the report. The firm cites less-than-expected growth of Provenge and concerns over growing competition.
From other sites
Comments (1)
  • Gary Jakacky
    , contributor
    Comments (2751) | Send Message
     
    Hahahahahahahahah

     

    Pro-venge: an overpriced ineffective drug.

     

    Neu-venge: an overpriced ineffective sequel.

     

    RE-VENGE: the joy of watchiing DNDN collapse...again!
    8 May 2012, 11:25 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs